Key result
Eight RNA therapeutics for cardiovascular indications are FDA-approved, with novel candidates advancing in the pipeline.
Why the study?
Eight RNA therapeutics with cardiovascular relevance have received US Food and Drug Administration approval and additional candidates are in the pipeline, warranting a summary of their mechanisms, clinical evidence, and future directions.
This review highlights the mechanistic basis, current clinical evidence for eight FDA-approved agents, and future pipeline of RNA therapeutics targeting key cardiovascular pathways such as lipoprotein(a), angiopoietin-like protein 3, and angiotensinogen.
Answers are grounded in this paper and cite their sources.
RNA therapeutics have reached FDA approval in cardiovascular medicine; leaves open optimal integration and outcome data for pipeline agents targeting lipoprotein(a).
RNA therapeutics are an exciting class of medications that target RNA and/or are themselves made from RNA. Most RNA therapeutics that have been approved for clinical use are antisense oligonucleotides or small interfering RNAs. To date, eight RNA therapeutics with cardiovascular relevance have received US Food and Drug Administration approval, but not all of them have specific indications for treating cardiovascular disease. There is a promising pipeline of additional cardiovascular RNA therapies targeting lipoprotein(a), angiopoietin-like protein 3, and angiotensinogen. Chemical modifications to therapeutic nucleic acids are important for conferring nuclease resistance and limiting immunostimulation in vivo, and enhanced delivery can be achieved using N -acetylgalactosamine conjugation and/or lipid nanoparticles. Emerging approaches include stereopure oligonucleotide chemistry, circular RNAs, adenosine-to-inosine RNA base editing, and nonhepatic targeting. This review summarizes the mechanistic basis of each modality, the clinical evidence for approved cardiovascular RNA therapeutics, selected pipeline candidates in advanced trials, and directions for future development.
No takes yet. Share an insight, caveat, or question.
Christopher L. Holley (2026) conducted a review in Cardiovascular disease. RNA therapeutics (antisense oligonucleotides, small interfering RNAs, and emerging modalities) was evaluated. Eight RNA therapeutics with cardiovascular relevance have received FDA approval to date, with promising pipeline candidates targeting lipoprotein(a), angiopoietin-like protein 3, and angiotensinogen.
Synapse has enriched 10 related papers. Consider them for comparative context: